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Cytogenetic analysis of unstimulated short-term bone marrow cell cultures was performed on 280 patients with multiple
myeloma and related disorders. In 65% of the cases, an additional short term B-cell stimulated culture was also examined.
Chromosomally abnormal clones were found in 31% of the patients, 15% in Waldenstro¨m macroglobulinemia, 25% in
monoclonal gammopathies, 33% in multiple myeloma, and 50% in plasma cell leukemia. Three primary chromosomal
breakpoints were recurrently involved: 14q32, 16q22, and 22q11. Structural rearrangements of chromosome 1 were the most
frequent (26% of the abnormal cases), but always as a secondary change. Rearrangements of band 14q32 were found in 22% of
the abnormal cases. Among the multiple myeloma patients who showed an abnormal karyotype, 33 (46%) were hyperdiploid,
most frequently with 52–56 chromosomes, 29 patients (40%) were pseudodiploid, and the remaining 12 cases (14%) were
hypodiploid. A highly significant relation was observed between the presence of an abnormal karyotype and the following
clinical parameters: stage III (P 5 0.0001), bone marrow plasma cell infiltration greater than 30% (P 5 0.0001), presence of bone
lesions (P 5 0.0009), and b2-microglobulin levels greater than 4 mg/L (P 5 0.0001). Genes Chromosom. Cancer 18:84–93, 1997.
r 1997 Wiley-Liss, Inc.
INTRODUCTION
The cytogenetic pattern of multiple myeloma
(MM) is rather less characteristic than that of any
other type of leukemia and lymphoma. So far,
around 800 cases of MM have been cytogenetically
reported (Cigudosa et al., 1994; Ankatil et al.,
1995; Laı¨ et al., 1995; Sawyer et al., 1995; Smadja et
al., 1995) and the main chromosomic features can
be summarized as follows: (1) The proportion of
abnormal karyotypes is about 40%, although it
varies greatly from series to series (20–60%). (2)
Abnormal clones appear to be evenly divided
between hypo-, pseudo-, and hyperdiploidy. (3)
The most common structural chromosomal abnor-
mality is a 14q1 marker which is either the result of
a reciprocal translocation, e.g., t(11;14)(q13;32) or
t(8;14)(q24;q32) or a more complex rearrangement
with unidentified chromosomes. (4) Other less
specific structural abnormalities frequently found
have been rearrangements of chromosomes 1, 6, 13,
17, 19, and 22.
Cytogenetic analysis has become of clinical inter-
est in MM patients, e.g., by identifying MM with
poor prognosis (those with chromosome abnormali-
ties; Dewald et al., 1985; Lisse et al., 1988); by dis-
tinguishing patients with plasma cell proliferation
who have cytopenia because of evolving therapy-
associated leukemia from those with progressive
bone marrow (BM) infiltration by plasma cells
(Dewald et al., 1985); and by detecting patients in
an advanced phase of the disease (Lewis and
Mackenzie, 1984). The karyotype in these patients
may be used as an independent prognostic factor
because of its correlation with other clinical param-
eters such as production of IgG3 (Van den Berghe
et al., 1984), BM plasma cell infiltration (Weh et al.,
1993; Cigudosa et al., 1994), clinical stage, b2-
microglobulin levels greater than 4,000 mg/ml, and
presence of bone lesions (Cigudosa et al., 1994).
To further clarify the cytogenetic features of
MM, we have analyzed the karyotype and other
hematological parameters of 280 patients with MM
and related disorders.
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MATERIALS AND METHODS
The study population included 217 patients with
MM, 44 patients with monoclonal gammopathies of
uncertain significance (MGUS) (we excluded plas-
mocytoma and MGUS associated to neoplasms or
to other diseases known to produce monoclonal
proteins), 13 patients withWaldestro¨mmacroglobu-
linemia (WM), and 6 patients with plasma cell
leukemia (PCL) (Table 1). MMwas defined accord-
ing to the diagnostic criteria of Durie and Salmon
(1975). Patient samples were collected in three
different Cytogenetic Services, members of the
Spanish Cooperative Group of Hematological Cyto-
genetics. The karyotypes of 20 patients (nos. 1
through 20) have been previously reported (Cigu-
dosa et al., 1994).
The following variables were studied at diagnosis
in each patient: age, sex, hemoglobin, creatinine,
b2-microglobulin, type of Ig, presence of bone
lesions, calcium, albumin, clinical stage, BM plasma
cell infiltration, chemotherapy if any, and karyo-
type. Table 2 summarizes data of some clinical
parameters that were found to be statistically signifi-
cant when correlated with the presence of chromo-
some abnormalities. Statistical comparisons were
made by Contingence Chi-square Test.
Cytogenetic studies were done on BM aspirates.
Two BM cultures were established from each
sample whenever possible (65% of the total num-
ber): one with a B-cell mitogen (pokeweed) and
one without mitogens. The culture medium was
McCoy’s 5A, Iwakata and Grace Modification,
supplemented with 20% fetal calf serum, gentami-
cine (50 mg/ml), L-glutamine (4 mM), and
pokeweed (0.8 mg/ml) when stimulated. Unstimu-
lated cultures were harvested within 24 hours of
incubation, whereas B-cell-stimulated cultures were
harvested after 48 hours of incubation. Both types
of cultures were exposed to Colcemid (0.1 mg/ml)
(Gibco BRL, Gaithersburg, MD) for 15 min, fol-
lowed by hypotonic treatment with KCl (0.075
mol/L) at 37°C for 7 min, and several washes with
fixative (methanol:acetic acid, 3:1). Slides were
prepared by the air-drying method. G-banding with
trypsin-Giemsa was used in all instances. C-
banding was performed by the baric hydroxid-
method when necessary. A minimum of 30 (mostly
50) well-spread metaphases were analyzed from
each case (or a minimum of 25 if all metaphases
showed the same chromosome aberration). Karyo-
types were described according to the ISCN (1991).
In order to convey the essential karyotypic features
in a more easily comprehensible manner, we have
illustrated the findings in a breakpoint map (see
TABLE 2. Summarized Clinical Data on the Multiple
Myeloma Patientsa
Clinical parameter
No. of
patients (%)
Stage (144 patients)
I 50 (35)
II 34 (23)
III 60 (42)
Type of immunoglobulin (160 patients)
IgG 101 (63)
IgA 38 (24)
IgD 1 (1)
Bence-Jones 15 (9)
Nonsecretory 3 (2)
Smoldering 2 (1)
b2-Microglobulin (mg/L; 145 patients)
#4 76 (52)
.4 69 (48)
Bone marrow infiltration (%; 147 patients)
#30 70 (48)
.30 77 (52)
Lytic lesions (146 patients)
No 67 (46)
Yes 79 (54)
Previous chemotherapy (158 patients)
No 74 (47)
Yes 84 (53)
aSex ratio (m/f): 1.45; median age, 63.3 (33–87) year; study period,
1/1990–12/1995.
TABLE I. Diagnosis and Cytogenetic Distribution of Patientsa
MM PCL WM MGUS Total
Normal 126 2 10 33 171
Abnormal 72 (33.2%) 3 (50%) 2 (15.4%) 11 (25%) 88 (31.4%)
Hyperdiploid 33 1 1 1 36
Hypodiploid 10 1 11
Pseudodiploid 29 2 1 9 41
Failure 19 1 1 21
Total 217 6 13 44 280
aMM, multiple myeloma; PCL, plasma cell leukemia; WM, Waldestro¨m macroglobulinemia; MGUS, monoclonal gammopathy of undetermined
significance.
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below). This was done according to the following
criteria, whose main aim was to avoid inflating any
existing nonrandomness when registering the
changes of clonal evolution:
1. If more than one copy of the same chromo-
some aberration was found in the same clone, the
breakpoints involved were plotted only once.
2. If the same chromosome aberration was found
in more than one related clone in any given case,
the breakpoints involved were plotted only once.
3. Whenever additional copies of a derivative
chromosome were further rearranged, in the same
or related clones, only the additional breakpoints
were plotted.
4. If the same breakpoint was involved in more
than one chromosome rearrangement in related
clones, it was plotted only once.
5. If the same breakpoint was involved in differ-
ent aberrations in unrelated clones, it was plotted
once per aberration.
6. In cases of rearrangements with uncertain
breakpoint localization, e.g., del(6)(q?), the break-
point was not included.
RESULTS
Cytogenetic Analysis
Table 1 shows the diagnostic distribution of the
280 patients together with the frequency of abnor-
mal karyotypes and the proportion of failed cul-
tures. On the whole, 7.5% of cases escaped cytoge-
netic analysis because of the absence or low number
of suitable metaphases. The proportion of cases
with chromosome alterations was 31%, but this
percentage varied between 15% in Waldenstro¨m
macroglobulinemia, 25% in monoclonal gammopa-
thies, 33% in multiple myeloma, and 50% in plasma
cell leukemia.
Breakpoints and Numerical Chromosome Changes
The complete descriptions of the chromosomally
abnormal clones, together with the proportion of
abnormal cells, are given in Table 3, and the
breakpoints are entered in the idiogram of Figure 1.
We have distinguished between primary and second-
ary breakpoints depending on whether or not they
are present as a single aberration in the karyotype.
It is noteworthy that primary breakpoints clustered
at 24 bands and that only 3 bands were frequently
involved: 14q32, 16q22, and 22q11. Primary chromo-
somal rearrangements of band 14q32 were observed
in 7 cases (cases 17, 30, 53, 70, 77, 83, and 87): Two
of them were t(8;14)(q24;q32) and one corre-
sponded to a t(11;14)(q13;q32). The remaining
were add(14)(q32) markers with unidentified chro-
mosomic segments. Deletions at band 16q22 were
found in 5 cases (cases 24, 28, 38, 80, and 82).
Deletions of chromosome 22 at band 22q11 were
found in 4 cases (cases 4, 12, 78, and 79). Represen-
tative partial karyotypes of these aberrations are
shown in Figure 2.
Secondary breakpoints were widely distributed
in all chromosomes but clustered to 81 bands (Fig.
1). The above mentioned primary breakpoints
(14q32, 16q22, and 22q11) were among them, thus
indicating their more specific role in the pathogen-
esis of MM. Adding together primary and second-
ary changes (Table 3), we found that 14q32 translo-
cations were themost frequent aberration, occurring
in 20 of 88 patients (23%). Less common were
rearrangements of 22q11 (14 out of 88 patients),
rearrangements of 16q22 (10 out of 88 cases), and
deletion 6q, which was present in 7 cases (Fig. 2).
Chromosome 1 structural aberrations were fre-
quently seen (25 cases), but always as a secondary
change. Breakpoints on chromosome 1 were scat-
tered throughout its length but clustered to the
centromere and bands p35-36. Less frequently,
bands 17p11, 2q32, and 11q13 were also affected by
secondary structural abnormalities. The reciprocal
translocation t(11;14)(q13;q32) was detected, as a
part of a more complex karyotype, in 2 cases (cases
32 and 37) (Fig. 2). Secondary deletions of the long
arms of chromosomes 5 and 7, usually described in
myelodysplastic syndromes and acute myeloid leu-
kemia, were detected in 4 cases (cases 29, 37, 45,
and 46) (Fig. 2).
Among the MM patients with abnormal karyo-
types (Table 1), 33 patients (46%) were hyperdip-
loid, most frequently with 52–56 chromosomes, 29
cases (40%) were pseudodiploid, and the remaining
12 cases (14%) were hypodiploid, mostly with 45
chromosomes with loss of one sex chromosome.
This trend towards hyperdiploidy was not observed
in the monoclonal gammopathies where 80% of the
abnormal cases were pseudodiploid. The most
frequent numerical anomalies were gains of chromo-
somes 3, 5, 7, 9, 11, 15, and 21. Monosomies were
less frequent than polysomies. Losses usually in-
volved chromosomes 8, 14, 2, 13, and Y (Fig. 3).
Monosomies, as the sole change in the karyotype,
were noted for the sex chromosomes (cases 14, 19,
and 22) and for chromosome 13 (case 11).
Karyotype and Clinical Evolution
Six patients were cytogenetically studied during
clinical management (Table 4). Three different
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TABLE 3. Chromosome Abnormalities in 88 Patients With MM and Related Disorders
Case
no.
Metaphases
(abnormal/ total) Classification Karyotype (only the abnormal clone)
MM
1a 15/33 AN 46,XY,del(20)(q12)
2 5/32 AN 66,XXX,21,der(1)t(1;?15)(p36;p13),del(1)(p36),22,14,14,15,28,19,110, 111,111,
212,213,214,217,218,219,220,220,221,del(22)(q11)x2
3 12/33 AN 66,XXX,21,23,23,25,16,27,2 8,19,111,112,113,214,115,217,217,118, 119,
220,221,del(22)(q11),1mar
4 10/32 AN 46,XY,del(22)(q11)/45,X,2Y,del(22)(q11)
5 25/25 AA 44,XX,dic(1;10)(p36;p15),210,i(17)(q10)
6 10/30 AN 43,XY,213,214,220,del(22)(q11)
7 11/28 AN 67,X,2X,der(X),21,i(2)(q10),24,15,16,add(6)(q12)x2,28,29,1i(11)(q10),212,213,
114,216,117,add(17)(p11)x2,118,118,219,220,122
8b 28/30 AN 94,XXYY,1del(22)(q11)x2
9 40/46 AN 86–8874n8,XXYY,26,214,del(17)(p11),219,219,222/175–17778n8, XXY,22,22,24,16,
17,29,29,210,211,112,214,1del(17)(p11)x2,220,220, 222
10 11/30 AN 58,XY,2X,24,28,29,210,211,212,add(14)(q32),216,217,218,220, 222,1mar
11 20/26 AN 45,XY,213
12 17/28 AN 46,XX,del(22)(q11)
13 31/31 AA 46,XX,add(17)(q25)
14 15/32 AN 45,X,2Y
15 12/30 AN 46,X,del(X)(q11)
16 20/30 AN 46,XX,add(12)(p12)
17 23/23 AA 46,XY,add(14)(q32)/46,idem,del(16)(q22)
18 23/30 AN 46,XX,t(7;12)(q32;q24)
19 10/30 AN 45,X,2Y
20 24/33 AN 46,X,2X,t(1;16)(p36;p13),25,17,1mar/46,X,2 X,t(1;16)(p36;p13), del(2)(q11),25,17,
del(11)(q21),del(20)(q13)
21 15/28 AN 46,X,2X,1mar/44,X,2X,add(1)(p11),del(6)(q21),28,213,1mar
22 26/39 AN 45,X,2X
23 10/100 AN 46,XX,del(1)(p21),inv(16)(q13q22)
24 27/40 AN 46,XX,del(16)(q22)
25 10/33 AN 46,XX,del(6)(q21),113,221
26 20/40 AN 47,XY,t(1;12)(p32;q24),1mar
27-1 25/50 AN 56,XY,1Y,1r(3)(p26q29),15,17,18,19,111,115,117,119
27-2 9/87 AN 55,XY,1Y,1r(3)(p26q29),15,18,19,115,117,119,1mar
27-3 20/100 AN 55,XY,1Y,1r(3)(p26q29),14,1dup(7)(p21),19,111,115,117,119
28 27/27 AA 46,XY,inv(9)(p21q13)c,del(16)(q22)
29 36/44 AN 42–44,X,add(X)(p11),11,t(2;13)(q32;q13),del(4)(q31),del(6)(q21), del(7)(q32),28,
dup(9)(q12q34),216,218,222,12mar[cp20]/85–99,MAKA
30 19/40 AN 46,XX,add(14)(q32)
31 14/25 AN 45,XY,2C
32 21/30 AN 46,XX,t(11;14)(q13;q32),der(15)t(1;15)(q12;p11)
33 43/43 AA 46,XX,add(12)(p12)
34 20/36 AN 46,XY,der(1)t(1;1)(p36;q10),13,i(8)(q10),der(13;15)(q10;q10)/80,XY,cx
35 6/31 AN 47,XY,1mar
36 7/30 AN 46,XY,add(14)(q32),add(16)(q22),del(22)(q11)/45,X,idem,2Y
37 36/42 AN 46,XY,del(5)(q13q22),der(10)t(1;10)(q11;p11),t(11;14)(q13;q32), der(14)t(11;14)
(q13;q32)/46,XY,del(5)(q13q22),t(11;14)(q13;q32), der(12)t(1;12)(q11;p11),
der(14)t(11;14)(q13;q32)
38 30/30 AA 46,XY,del(16)(q22)
39 15/40 AN 60,XY,2X,11,del(1)(p?),t(2;7)(q22;q23),13,del(3)(p?),24,26,212,213,
214,add(14)(q32),115,216,217,219,220,221,222
40 18/30 AN 52,XY,110,i(10q),111,114,115,116,1mar
41 25/25 AA 44,X,2X,11,t(1;8;18)(p32;p23;q12),t(1;3)(q11;p21),29,inv(13)(p13q22),
add(14)(q32),216
42 33/33 AA 46,XY,22,24,1mar1,1mar2
43 27/27 AA 49,XY,i(1)(q10),t(4;11)(q28;q24),29,t(10;16)(q22;q22),115,121,1mar1,1mar2/46,XY,
t(4;9)(q34;q11)/46,XY,dmin
44 37/37 AA 48,XY,15,16,17,28,210,del(14)(q24qter),115
45 7/30 AN 55,XX,del(5)(q21q33),del(6)(q12),111,111,t(11;12)(q14;p12),113,114,115,
116,117,118,219,121,12mar
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types of clinical evolutions were observed. First,
the karyotype demonstrated complete or partial
remission during therapy (cases 15, 20, and 24).
Secondly, persistence of clonal abnormalities corre-
lated with lack of response to treatment in case 27.
And finally, the appearance of complex structural
rearrangements in cases 37 and 46 was followed by
the early death of both patients.
TABLE 3. Chromosome Abnormalities in 88 Patients With MM and Related Disorders (continued)
Case
no.
Metaphases
(abnormal/ total) Classification Karyotype (only the abnormal clone)
46 25/25 AA 46,XY,del(7)(q36),29,111,del(16)(q?),add(17)(q?)/51,XY,del(7)(q36),29, 111,
del(16)(q?),add(17)(q?),15mar
47 27/27 AA 53,XY,del(2)(q?),13,del(4)(q?),del(6)(q?),17,add(7)(q?),111,121,122,1mar1, 1mar2
48 30/30 AA 49,XY,1t(1;21)(q21;q11),13,del(3)(q?),t(11;22)(p13;q11),117
49 25/25 AA 46,XY,dup(1)(q11q25)
50 17/42 AN 46,XY,del(1)(p31)
51 14/31 AN 46,XX,del(1)(p?)
52 25/25 AA 57,XY,1del(3)(q?),14,17,18,19,111,111,113,120,121,del(22)(q11),1mar
53 25/25 AA 46,XY,add(14)(q32)/38–49,XY,1der(1),add(14)(q32),218,119,120, 121[cp10]
54 8/35 AN 46,XX/80,MAKA,der(1),del(22)(q11)
55 15/50 AN 52,XY,1Y,15,del(6)(q15),111,114,115,add(17)(p11),1mar
56 18/35 AN 53,XX,12,13,15,16,111,117,119
57 10/30 AN 77,XXY,1Y,22,24,28,19,111,113,114,114,117,218,121,121,13mar
58 20/40 AN 48,XY,15,19,add(13)(q34),add(14)(q32)
59 12/30 AN 46,XX,dmin
60 22/35 AN 48,XX,19,114
61 8/30 AN 92,XXXX
62 13/33 AN 56,XX,del(1)(q32),del(3)(q21),add(5)(p15),18,1add(9)(p22),add(11)(p15),
1add(11)(p15)x2,114,115,118,121,12mar
63 10/30 AN 49,XY,15,t(8;22)(q24;q11),111,119
64 11/35 AN 89,XXXX,25,210,214,215,219,220,222,14mar
65 30/30 AA 45,XX,der(13;14)(q10;q10)
66 12/50 AN 78,XXY,1Y,11,17,111,112,114,117,119,120
67 19/35 AN 46,XY,del(6)(q23)
68 13/50 AN 46,XX,11,1der(1)t(1;15)(q10;p10)/92–123,XXXX[cp8]
69 35/35 AA 46,XY,dup(1)(q12q22)
70 30/30 AA 46,XX,t(11;14)(q13;q32)
71 17/66 AN 45,X,2Y
72 28/43 AN 46,XY/42,XY,der(1),1der(1)del(1)(p13),der(2)t(2;3)(q32;q24),25,28,210, 213,
der(14;21)(q10;q10),1der(15)x2,216,der(17)t(10;17)(q23;q23),218
MGUS
73 22/75 AN 47,XX,1mar/90–95,pvz
74 15/35 AN 45,XX,28,del(17)(p13)/45,idem,del(22)(q13)
75 24/50 AN 46,XX,der(1;4)(q10;q10),del(6)(q21),add(14)(q32),del(16)(q22)
76 28/28 AA 46,XY,add(17)(q25)
77 30/30 AA 46,XY,t(8;14)(q24;q32)
78 22/36 AN 46,XX,del(22)(q11)
79 20/35 AN 46,XX,del(22)(q11)
80 16/36 AN 46,XY,del(16)(q22)
81 28/28 AA 46,XY,inv(11)(p12p14)
82 16/30 AN 46,XY,del(16)(q22)
83 26/26 AA 46,XY,inv(9)(p11q13)c/46,idem,add(14)(q32)
PCL
84 25/25 AA 46,XX,add(4)(p15),del(10)(q22),add(14)(q32)
85 26/26 AA 46,XX,del(1)(q21),1der(1),25,28,add(12)(q22),214,add(14)(q32), 12mar
86 32/32 AA 46–47,XY,del(1)(q21),add(14)(q32),MAKA
WM
87 30/30 AA 46,XY,t(8;14)(q24;q32)
88 27/27 AA 48,Y,2X,dup(1)(p13p22),del(2)(p12),add(2)(q32),14,del(6)(q15q21), add(7)(p22),
i(8)(q10),add(14)(q32),1add(17)(p11),1mar
aPatient with a deletion 20q-associated with previous polycythemia vera.
bKaryotype with complex rearrangements with an identifiable del(22)(q11).
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Clinical Parameters and Karyotype
In order to confirm our preliminary results, con-
tingence tests were performed to determine the
influence of the clinical parameters recorded for
each patient on the chromosomal aberration rate.
Stage, bone lesions, b2-microglobulin level, BM
plasma cell infiltration, and previous chemotherapy
influenced the karyotype. The remaining param-
eters showed no statistically significant relationship
with the abnormality rate.
As shown in Table 5, a highly significant relation
existed between the presence of an abnormal
karyotype and stage III, levels of b2-microglobulin
greater than 4 mg/L, lytic bone lesions, more than
30% of BM plasma cell infiltration, and previous
chemotherapy.
DISCUSSION
To find specific chromosome abnormalities in
MM has been difficult, mostly owing to the low
mitotic index of the cells implicated in the disease.
Many efforts have been made to obtain an elevated
number of cells suitable for cytogenetic analysis.
The commonest strategies have been the use of
hemopoietic growth factors such as cytokines (Fa-
con et al., 1993; Laı¨ et al., 1995; Smadja et al., 1995)
or other known B-cell mitogens such as lipopolysac-
charide (Taniwaki et al., 1994) or pokeweed (Cigu-
Figure 1. Diagrammatic representation of the 24 primary and 81 secondary chromosomal breakpoints
involved in structural abnormalities in the 88 patients. Clustering was noted on chromosome bands 14q32,
16q22, and 22q11. Triangles represent primary breakpoints and circles represent secondary breakpoints.
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dosa et al., 1994). However, controversial results
have been reported when cytokine-stimulated cul-
tures are used. Laı¨ et al. (1995) found that the
abnormality detection rate was higher when 2,000
IU/mL of interleukine 6 (IL-6) was used. On the
other hand, after using the same concentration of
IL-6, Smadja et al. (1995) suggested that, at least for
stage III multiple myeloma at diagnosis, a 3 day
culture without cytokine was the best technique to
detect clonal chromosomal abnormalities. For this
study, the patient samples were collected in three
different cytogenetic services which are members
of the Spanish Cooperative Group of Hematologi-
cal Cytogenetics. Only one of them used pokeweed
as a mitogen and it was able to examine more than
30 metaphases from each patient (65% of the total
number of samples). This method was reported to
detect abnormal metaphases in 49% of cases (Cigu-
dosa et al., 1994), which is very close to the
proportion observed in studies where cytokines
Figure 2. Structural abnormalities involving chromosomes 6, 7, 11, 14, 16, and 22. A: Four examples of
add(14)(q32); B: four examples of del(6q); C: four examples of del(7q); D1: four examples of G-banded
del(16q); D2: four examples of C-banded del (16q); E: four examples of del (22)(q11); F: two examples of
the t(11;14)(q13;q32) from MM patient 37, obtained from two metaphase cells (1) and (2). Arrowheads
indicate breakpoints.
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Figure 3. Frequency of numeric changes in 88 patients with abnormal karyotype.
TABLE 4. Clinical Evolution of Karyotype in Six Patients With Multiple Myeloma
Case
no.
Date
(month/
year)
Myeloma
protein type
Clinical
stage
Previously
treated
Metaphases
(abnormal/
total) Karyotype
15 3/93 MM Bence-Jones k III-A Yes (30/30) 46,X,del(X)(q11)
5/93 idem idem Post-transplan-
tation
(12/30) 46,XX/46,X,del(X)(q11)
20 10/93 MM Bence-Jones l II-A Yes (24/33) 46,XX/46,X,2X,t(1;16)(p36;p13),25,17,1mar/46,
X,2X,t(1;16)(p36;p13), del(2)(q11),25,17,
del(11)(q21),del(20)(q13)
4/94 idem idem Yes (0/30) 46,XX
27 4/94 MM IgA k II-A At diagnosis (25/50) 46,XY/55,XY,1Y,1r(3),15,17,18,19,111,115,
117,119
12/94 idem idem Yes (9/87) 46,XY/55,XY,1Y,1r(3),15,18,19,115,117,119,
1mar
1/95 idem idem Yes (20/100) 46,XY/55,XY,1Y,1r(3)(p26q29),14,1dup(7)(p21),
19,111,115,117,119
24 12/94 MM IgG k III-A At diagnosis (30/30) 46,XX,del(16)(q22)
5/95 idem idem Yes (27/40) 46,XX/46,XX,del(16)(q22)
37 12/93 MM Bence-Jones l III-B At diagnosis (0/28) 46,XY
11/95 idem idem Yes (exitus) (36/42) 46,XY,del(5)(q13q22),der(10)t(1;10)(q11;p11),
t(11;14)(q13;q32), der(14)t(11;14)(q13;q32)/46,
XY,del(5)(q13q22),t(11;14)(q13;q32),der(12)
t(1;12)(q11;p11),der(14)t(11;14)(q13;q32)
46 1/92 MM IgG l II-B Yes (0/50) 46,XY
8/93 idem III-B Yes (exitus) (25/25) 46,XY,del(7)(q36),29,111,del(16)(q?),add(17)(q?)/51,
XY,del(7)(q36),29, 111,del(16)(q?),add(17)(q?),
15mar
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were used (Laı¨ et al., 1995). Nevertheless, when all
samples here presented were taken together, the
proportion of cases with chromosomal abnormali-
ties was lower (31%) and similar to the proportion
reported by other groups which did not use mito-
gens or growth factors (Dewald et al., 1985; Weh et
al., 1993; Sawyer et al., 1995).
Only 32% of the karyotypically abnormal pa-
tients had chromosome anomalies in all meta-
phases; in the remaining cases, mosaicism with a
varying proportion of normal cells was noted (Table
2). It has been confirmed that normal metaphases
in MM originate from hematopoietic cells other
than plasma cells (Weh et al., 1990; Guthensohn et
al., 1992; Weh et al., 1993). For this reason, until a
more accurate system of culturing plasma cells is
detected, we suggest the use of any medium that
allows an exhaustive analysis of a large number of
metaphases to avoid misinterpretation of normal
karyotypes.
The breakpoint analysis in our series points out
the existence of three bands that are primarily
implicated in MM (Fig. 1): 14q32, 16q22, and
22q11. The essential role played by these bands is
confirmed by their persistence also as common
secondary breakpoints.
As expected from previous reports, rearrange-
ments of 14q32 were the most frequent, found in
23% of the abnormal cases. This proportion falls
within the reported range for MM when larger
series are analyzed (Dewald et al., 1985; Weh et al.,
1993; Laı¨ et al., 1995; Sawyer et al., 1995). The high
prevalence of t(11;14)(q13;q32) was also observed
in our series and identified as the most frequent
rearrangement of band 14q32 (three cases out of the
five samples where the structural rearrangement of
this band was fully characterized). We found rear-
rangements affecting 16q22 in 10% of the abnormal
cases. This anomaly has been rarely reported in
MM. Recently, Sawyer et al. (1995) described
monosomy for chromosome 16 in 12 out of 63
abnormal patients and deletion of 16q in another 3.
They noticed that this monosomy, together with
monosomy 13, occurred in 7 of the 8 untreated
patients of their series. Based on these data, they
suggested that the loss of chromosomes or chromo-
some segments may have a significant role in the
cytogenetic progression of MM.We fully agree with
this suggestion since we have also observed mono-
somy or loss of 16q material in a relatively high
proportion of abnormal cases. More specifically,
four patients showed a deletion del(16)(q22) as the
sole anomaly in their karyotype.
We detected structural rearrangements of band
22q11, mostly del(22)(q11), in 16% of the abnormal
cases. This anomaly has rarely been described as a
primary change in MM (Van den Berghe et al.,
1979; Karpas et al., 1982; Cigudosa et al., 1994)
although it was found as a secondary change in most
of the reports where more than 100 patients were
studied (Weh et al., 1993; Laı¨ et al., 1995; Sawyer et
al., 1995). The observed frequency of aberrations
affecting 22q11 ranges from 5% found in cytokine
stimulated cultures (Laı¨ et al., 1995) to 16% in the
present study, where a B-cell mitogen was used.
Numerical changes were the same as those seen
in previous studies and involved gains of chromo-
somes 3, 5, 7, 9, 11, 15, 19, and/or 21. A similarly
striking pattern has already been described for
thyroid tumors (Belge et al., 1994).
Based on DNA aneuploidy (Garcı´a-Sanz et al.,
1995) and FISH studies (Drach et al., 1995a), it is
accepted that numerical chromosomic changes are
present in the majority (80–90%) of MM cases.
Moreover, aneuploidy has also been detected in
more than 50% of MGUS patients (Drach et al.,
1995b). Thus, it seems clear that some chromosom-
ally abnormal cases escaped cytogenetic analysis.
However, it should be underlined that the DNA-
ploidy and FISH approaches tell us nothing about
the distinct structural aberrations or the primary
breakpoints involved in the pathogenesis of this
disease. It is also important to notice that, so far, no
structural cytogenetic aberrations have been de-
scribed for MGUS patients. We present here 11
cases of MGUS which showed chromosomic rear-
rangements. Their karyotypic features were similar
to those described for MM with primary involve-
TABLE 5. Significant Dependence Between Clinical Param-
eters and Chromosomal Aberration Rate
Clinical parameter
No. of patients with
abnormal karyotype (%) P value
b2-Microglobulin (mg/L)
#4 18 (24) 0.0001
.4 39 (57)
Bone marrow infiltration (%)
#30 13 (19) 0.0001
.30
48 (62)
Stage
I 6 (12) 0.0001
II 16 (47)
III 39 (65)
Lytic lesions
No 16 (24) 0.0009
Yes 40 (51)
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ments of 14q32, 16q22, and 22q11. For this reason,
they have been managed as MM patients only from
the cutogenetic point of view.
The clinical importance of cytogenetic analysis
in MM patients is evident. As a method to monitor
treatment, it can be used to detect progression or
lack of response (Table 3). Of the six patients who
were cytogenetically monitored during clinical man-
agement, it is noteworthy that those with 16q22
rearrangement showed complete or partial disap-
pearance of the abnormal clone. It has been re-
cently reported that partial or complete deletions of
chromosome 13 or abnormalities involving 11q are
associated with a poor prognosis (Tricot et al., 1995).
For this purpose, a complete statistical survival
analysis is being performed at our center to detect
the prognostic value of the different chromosomal
anomalies, but the study period is not yet closed
and this issue will be addressed in the future. As we
have previously reported in a series of 41 patients,
the incidence of chromosomal anomalies was influ-
enced by some clinical parameters (Cigudosa et al.,
1994). In this report, which includes 280 patients,
we confirm our results and obtain a higher statistical
significance (Table 5) for the association between
an abnormal karyotype and a high level of b2-
microglobulin, dense bone lesions, bone marrow
plasma cell infiltration, and stage III, which are all
characteristics of advanced disease.
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